Studies have demonstrated CBD’s proficiency to treat inflammation with the ability to remedy a number of physical and mental illnesses. Compounds with anti-inflammatory properties are highly prized in both wellness and medical markets, and CBD has the added benefits of antibacterial and antiviral attributes. With the popularity of tinctures, topicals and capsules promoting increased consumer accessibility and adoption, the global CBD market is expected to surpass $13 billion in revenue by 2028. The EU cosmetic ingredient database determined that cannabinoids can be used in cleansers and conditioners, with hemp-based CBD oil particularly revered as it rejuvenates damaged skin.
Producers of consumer packaged goods regularly partner with industry specialists to achieve the highest quality and consistency which ensures optimal efficacy and elevates their products above the competition. The CBD industry is no exception, but with a lack of unified regulations it can be difficult to source premium CBD and CBD products that can be exported worldwide.
A chasm exists between wellness and medical markets, with active ingredients in the latter held to a higher standard. For medical products, clinical trials are mandated in patient populations to demonstrate safety and efficacy in order to gain regulatory approval. In wellness markets, this due diligence is not legally required and therefore rarely conducted, despite the products often being consumed in the same way. In loosely governed wellness markets, CBD products have been found to contain contaminants, a different potency than advertised and in some cases absent of the cannabinoid entirely.
